Coeur Mining
CDE
10.68
-0.86
-7.45%
Coeur Mining
US · CDE
#988 by market cap
Listed 1970
10.68
-0.86
-7.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:57
Recent news
-
Company notice
Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE ReviewSZSI · 2026/6/18
-
Rating change
Roth MKM Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $21Market Newswire · 2026/7/17
-
Rating change
Roth MKM Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $17Market Newswire · 2026/10/29
-
Rating change
Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $26.5Market Newswire · 2026/11/5
-
Company notice
Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE ReviewSZSI · 2026/6/3
-
Rating change
A Quick Look at Today's Ratings for Coeur Mining(CDE.US), With a Forecast Between $18 to $26.5Market Newswire · 2026/8/7
-
Rating change
BMO Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $26Market Newswire · 2026/8/6
-
CIBC Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $27Market Newswire · 2026/11/6
-
Company notice
Tianyu Co., Ltd.: Announcement Regarding the Approval of Its Wholly-Owned Subsidiary's Active Pharmaceutical Ingredient by the CDE ReviewSZSI · 2026/10/30
-
Rating change
Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Raises Target Price to $28.5Market Newswire · 2026/7/15
-
Roth MKM Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $16Market Newswire · 2026/11/6
-
Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $23.5Market Newswire · 2026/11/9
-
Company notice
Tianyu Co., Ltd.: Announcement Regarding the Approval of Its Wholly-Owned Subsidiary's Active Pharmaceutical Ingredient by the CDE ReviewSZSI · 2026/9/5
-
Company notice
Tianyu Co., Ltd.: Announcement Regarding the Approval of the Company\'s Active Pharmaceutical Ingredient by the CDE ReviewSZSI · 2026/7/14
-
Rating change
ATB Cormark Capital Markets Downgrades Coeur Mining(CDE.US) to Hold Rating, Cuts Target Price to $18Market Newswire · 2026/8/7
-
Rating change
Scotiabank Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $28.5Market Newswire · 2026/7/23
-
Rating change
Scotiabank Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $27.5Market Newswire · 2026/6/12
-
Jiuyuan Gene is surging after the CDE officially accepted its IND application for JY54-2 injection, which targets two indications.Zhitong Finance · 2026/11/19
-
RBC Capital Initiates Coeur Mining(CDE.US) With Buy Rating, Announces Target Price $23Market Newswire · 2026/11/10
-
Rating change
RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $23Market Newswire · 2026/10/14
-
Rating change
RBC Capital Maintains Coeur Mining(CDE.US) With Buy Rating, Cuts Target Price to $23Market Newswire · 2026/6/4
-
Earnings Flash (CDE) Coeur Mining, Inc. Posts Q3 Adjusted EPS $0.10 per Share, Vs. FactSet Est of $0.14MT Newswires · 2026/11/5
-
Earnings Flash (CDE) Coeur Mining, Inc. Reports Q3 Revenue $983.6M, Vs. FactSet Est of $1.14BMT Newswires · 2026/11/5
-
Company notice
Tianyu Co., Ltd.: Announcement Regarding the Approval of Active Pharmaceutical Ingredients by the CDESZSI · 2026/5/8
-
Scotiabank Maintains Coeur Mining(CDE.US) With Buy Rating, Maintains Target Price $26.5Market Newswire · 2026/9/23
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:57:15 · For reference only, not investment advice and not tailored to your situation.
Coeur Mining discussion 0 comments